SELF-INTRODUCTION：

Dr. Rongquan Xiao is a research assistant professor in the School of Medicine at SUSTech. He completed his Ph.D. studies under Dr. Wen Liu's supervision at Xiamen University in 2020, and he stayed in Dr. Wen Liu’s lab for postdoctoral training during the next three years. He has broad research interests in studying the functions, molecular mechanisms, and therapeutic strategies of cancer-associated genes. His research work has been published in journals such as Molecular Cell, Proc Natl Acad Sci U S A, and ACS Medicinal Chemistry Letters. His research was supported by projects from the National Natural Science Foundation projects, the China Postdoctoral Science Foundation, and Shenzhen Medical Research Funding.

EDUCATION:

2014/09 - 2020/06 Ph.D., Chemical Biology, Xiamen University

2009/09 - 2013/07 B.S., Biotechnology, Shanghai Normal University

WOKRING EXPERIENCE:

2023/06 – now  Research Assistant Professor, School of Medicine, Southern University of Science and Technology

2020/07 - 2023/06 Postdoc fellow, School of Pharmaceutical Sciences, Xiamen University

HONORS AND AWARDS:

2020, Outstanding Graduates of Xiamen University

RESEARCH:

The molecular mechanism underlying epigenetic regulation of gene expression and its implications in cancer development

PUBLICATIONS：

1. Xiao RQ, Ran T, Huang QX, Hu GS, Fan DM, Yi J, Liu W. A specific JMJD6 inhibitor potently suppresses multiple types of cancers both in vitro and in vivo. Proc Natl Acad Sci U S A. 2022 Aug 23;119(34): e2200753119.

2. Gao WW#, Xiao RQ#, Zhang WG#, Hu YR#, Peng BL, Li WJ, He YH, Shen HF, Ding JC, Huang QX, Ye TY, Li Y, Liu ZY, Ding R, Rosenfeld MG, Liu W. JMJD6 licenses estrogen receptor a-dependent enhancer and coding gene activation by modulating the recruitment of the CARM1/MED12 co-activator complex. Molecular Cell. 2018 April 19;70(2): 340-357. (# joint 1st authors)

3. Ran T#, Xiao RQ#, Huang QX, Yuan HL, Lu T, Liu W. In Silico Discovery of JMJD6 Inhibitors for Cancer Treatment. ACS Medicinal Chemistry Letters. 2019 Nov 19, 10: 1609-1613. (# joint 1st authors)

4. Gao WW, Xiao RQ, Peng BL, Xu HT, Shen HF, Huang MF, Shi TT, Yi J, Zhang WJ, Wu XN, Gao X, Lin XZ, Dorrestein PC, Rosenfeld MG, Liu W. Arginine methylation of HSP70 regulates retinoid acid-mediated RARβ2 gene activation. Proc Natl Acad Sci U S A. 2015 Jun 30;112(26): E3327-36.

5. Yi J, Wang L, Du J, Wang MY, Shen HF, Liu ZY, Qin Y, Liu J, Hu GS, Xiao RQ, Ding JC, Chen HJ, Wang HJ, Huang HH, Ouyang GL, Liu W. ER-localized JmjC domain-containing protein JMJD8 targets STING to promote immune evasion and tumor growth in breast cancer. Developmental Cell. 2023 May 8, 58(9): 760-778.

6. Peng BL, Li WJ, Ding JC, He YH, Ran T, Xie BL, Wang ZR, Shen HF, Xiao RQ, Gao WW, Ye TY, Gao X, Liu W. A hypermethylation strategy utilized by enhancer-bound CARM1 to promote estrogen receptor a-dependent transcriptional activation and breast carcinogenesis. Theranostics. 2020 Feb 10; 10(8): 3451-3473.

7. Zhang WJ, Wu XN, Shi TT, Xu HT, Yi J, Shen HF, Huang MF, Su XY, Wang FF, Peng BL, Xiao RQ, Gao WW, Ding JC, Liu W. Regulation of Transcription Factor Yin Yang 1 by SET7/9-mediated Lysine Methylation. Scientific Reports. 2016 Feb 23; 6: 21718.

8. Ye F, You J, Xia L, Lian JB, Xiao RQ, Ran T, Gao X, Li JY, Zhao X, Gao J, Lin HX, Zheng JN, Liu W. Patient-derived xenografts (PDX) identify JMJD6 inhibitor as an effective therapeutic medicine in colorectal cancer. Annals of Oncology. 2019 Oct; 30: v238-v239.